胶质细胞瘤的侵袭机制及分子靶向治疗研究进展

被引:8
作者
刘柏麟
章翔
机构
[1] 第四军医大学西京脑科医院神经外科
关键词
胶质细胞瘤; 侵袭; 分子靶向治疗;
D O I
暂无
中图分类号
R739.4 [神经系肿瘤];
学科分类号
100115 [医学神经生物学];
摘要
引用
收藏
页码:568 / 571
页数:4
相关论文
共 11 条
[1]
胶质瘤的靶向放射治疗及分子靶向治疗 [J].
石梅 ;
魏丽春 .
中华神经外科疾病研究杂志, 2006, (04) :289-291
[2]
神经系统肿瘤学.[M].章翔主编;.军事医学科学出版社.1999,
[3]
Integrins: Molecular targets in cancer therapy [J].
Tucker G.C. .
Current Oncology Reports, 2006, 8 (2) :96-103
[4]
Sorafenib:: Recent update on activity as a single agent and in combination with interferon-α2 in patients with advanced-stage renal cell carcinoma [J].
Reddy, G. Kesava ;
Bukowski, Ronald M. .
CLINICAL GENITOURINARY CANCER, 2006, 4 (04) :246-248
[5]
Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme.[J].Fabian Baumann;Miroslava Bjeljac;Spyros S. Kollias;Brigitta G. Baumert;Sebastian Brandner;Valentin Rousson;Yasuhiro Yonekawa;René L. Bernays.Journal of Neuro-Oncology.2004, 1
[6]
ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor [J].
Kodama, T ;
Ikeda, E ;
Okada, A ;
Ohtsuka, T ;
Shimoda, M ;
Shiomi, T ;
Yoshida, K ;
Nakada, M ;
Ohuchi, E ;
Okada, Y .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (05) :1743-1753
[7]
Soluble factors involved in glioma invasion [J].
Mueller, MM ;
Werbowetski, T ;
Del Maestro, RF .
ACTA NEUROCHIRURGICA, 2003, 145 (11) :999-1008
[8]
Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times [J].
Goetz, C ;
Riva, P ;
Poepperl, G ;
Gildehaus, FJ ;
Hischa, A ;
Tatsch, K ;
Reulen, HJ .
JOURNAL OF NEURO-ONCOLOGY, 2003, 62 (03) :321-328
[9]
Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist [J].
MacDonald, TJ ;
Taga, T ;
Shimada, H ;
Tabrizi, P ;
Zlokovic, BV ;
Cheresh, DA ;
Laug, WE .
NEUROSURGERY, 2001, 48 (01) :151-157
[10]
Ongoing trials with matrix metalloproteinase inhibitors [J].
Brown, PD .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) :2167-2177